Absence of gelatinase (MMP-9) or collagenase (MMP-13) attenuates adriamycin-Induced albuminuria and glomerulosclerosis

Yusuke Sakamaki, Hiroyuki Sasamura, Kaori Hayashi, Kimiko Ishiguro, Hironari Takaishi, Yasunori Okada, Jeanine M. D'Armiento, Takao Saruta, Hiroshi Itoh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background/Aims: The role of matrix metalloproteinases (MMPs) in the pathogenesis of glomerular injury appears to be complex. To investigate the role of individual MMPs, we examined the course of Adriamycin-induced albuminuria and glomerulosclerosis in mice lacking either a gelatinase (MMP-9) or a collagenase (MMP-13). Methods: Adriamycin was administered to MMP-9 or MMP-13 knockout (KO) mice. Glomerular injury was assessed by the quantification of albuminuria, the glomerular injury score and type IV collagen immunostaining. Results: Treatment of mice with Adriamycin (18 mg/kg i.v.) resulted in marked albuminuria and glomerulosclerosis reaching a peak at 4-8 weeks. The albuminuria and glomerulosclerosis were significantly (p < 0.05) attenuated in both the MMP-9 KO and MMP-13 KO mice compared to controls. In contrast, treatment of wild-type mice with the broad-spectrum MMP inhibitor doxycycline did not have a beneficial effect on the albuminuria and glomerulosclerosis. Conclusion: These results support a role for both gelatinase (MMP-9) and collagenase (MMP-13) in the pathogenesis of glomerular injury in the Adriamycin-induced glomerulosclerosis model. MMP inhibitors with high specificity towards MMP-9 and/or MMP-13 may be potential future candidates to provide more effective therapies to inhibit the development of glomerulosclerosis.

Original languageEnglish
JournalNephron - Experimental Nephrology
Volume115
Issue number2
DOIs
Publication statusPublished - 2010 Jun

Fingerprint

Matrix Metalloproteinase 13
Gelatinases
Albuminuria
Matrix Metalloproteinase 9
Collagenases
Doxorubicin
Matrix Metalloproteinase Inhibitors
Wounds and Injuries
Matrix Metalloproteinases
Knockout Mice
Collagen Type IV
Doxycycline

Keywords

  • Adriamycin
  • Glomerulosclerosis
  • Matrix metalloproteinase

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Genetics

Cite this

Absence of gelatinase (MMP-9) or collagenase (MMP-13) attenuates adriamycin-Induced albuminuria and glomerulosclerosis. / Sakamaki, Yusuke; Sasamura, Hiroyuki; Hayashi, Kaori; Ishiguro, Kimiko; Takaishi, Hironari; Okada, Yasunori; D'Armiento, Jeanine M.; Saruta, Takao; Itoh, Hiroshi.

In: Nephron - Experimental Nephrology, Vol. 115, No. 2, 06.2010.

Research output: Contribution to journalArticle

Sakamaki, Yusuke ; Sasamura, Hiroyuki ; Hayashi, Kaori ; Ishiguro, Kimiko ; Takaishi, Hironari ; Okada, Yasunori ; D'Armiento, Jeanine M. ; Saruta, Takao ; Itoh, Hiroshi. / Absence of gelatinase (MMP-9) or collagenase (MMP-13) attenuates adriamycin-Induced albuminuria and glomerulosclerosis. In: Nephron - Experimental Nephrology. 2010 ; Vol. 115, No. 2.
@article{a71ae3fd565745b6b8336e30dfed9173,
title = "Absence of gelatinase (MMP-9) or collagenase (MMP-13) attenuates adriamycin-Induced albuminuria and glomerulosclerosis",
abstract = "Background/Aims: The role of matrix metalloproteinases (MMPs) in the pathogenesis of glomerular injury appears to be complex. To investigate the role of individual MMPs, we examined the course of Adriamycin-induced albuminuria and glomerulosclerosis in mice lacking either a gelatinase (MMP-9) or a collagenase (MMP-13). Methods: Adriamycin was administered to MMP-9 or MMP-13 knockout (KO) mice. Glomerular injury was assessed by the quantification of albuminuria, the glomerular injury score and type IV collagen immunostaining. Results: Treatment of mice with Adriamycin (18 mg/kg i.v.) resulted in marked albuminuria and glomerulosclerosis reaching a peak at 4-8 weeks. The albuminuria and glomerulosclerosis were significantly (p < 0.05) attenuated in both the MMP-9 KO and MMP-13 KO mice compared to controls. In contrast, treatment of wild-type mice with the broad-spectrum MMP inhibitor doxycycline did not have a beneficial effect on the albuminuria and glomerulosclerosis. Conclusion: These results support a role for both gelatinase (MMP-9) and collagenase (MMP-13) in the pathogenesis of glomerular injury in the Adriamycin-induced glomerulosclerosis model. MMP inhibitors with high specificity towards MMP-9 and/or MMP-13 may be potential future candidates to provide more effective therapies to inhibit the development of glomerulosclerosis.",
keywords = "Adriamycin, Glomerulosclerosis, Matrix metalloproteinase",
author = "Yusuke Sakamaki and Hiroyuki Sasamura and Kaori Hayashi and Kimiko Ishiguro and Hironari Takaishi and Yasunori Okada and D'Armiento, {Jeanine M.} and Takao Saruta and Hiroshi Itoh",
year = "2010",
month = "6",
doi = "10.1159/000312883",
language = "English",
volume = "115",
journal = "Experimental Nephrology",
issn = "1660-8151",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Absence of gelatinase (MMP-9) or collagenase (MMP-13) attenuates adriamycin-Induced albuminuria and glomerulosclerosis

AU - Sakamaki, Yusuke

AU - Sasamura, Hiroyuki

AU - Hayashi, Kaori

AU - Ishiguro, Kimiko

AU - Takaishi, Hironari

AU - Okada, Yasunori

AU - D'Armiento, Jeanine M.

AU - Saruta, Takao

AU - Itoh, Hiroshi

PY - 2010/6

Y1 - 2010/6

N2 - Background/Aims: The role of matrix metalloproteinases (MMPs) in the pathogenesis of glomerular injury appears to be complex. To investigate the role of individual MMPs, we examined the course of Adriamycin-induced albuminuria and glomerulosclerosis in mice lacking either a gelatinase (MMP-9) or a collagenase (MMP-13). Methods: Adriamycin was administered to MMP-9 or MMP-13 knockout (KO) mice. Glomerular injury was assessed by the quantification of albuminuria, the glomerular injury score and type IV collagen immunostaining. Results: Treatment of mice with Adriamycin (18 mg/kg i.v.) resulted in marked albuminuria and glomerulosclerosis reaching a peak at 4-8 weeks. The albuminuria and glomerulosclerosis were significantly (p < 0.05) attenuated in both the MMP-9 KO and MMP-13 KO mice compared to controls. In contrast, treatment of wild-type mice with the broad-spectrum MMP inhibitor doxycycline did not have a beneficial effect on the albuminuria and glomerulosclerosis. Conclusion: These results support a role for both gelatinase (MMP-9) and collagenase (MMP-13) in the pathogenesis of glomerular injury in the Adriamycin-induced glomerulosclerosis model. MMP inhibitors with high specificity towards MMP-9 and/or MMP-13 may be potential future candidates to provide more effective therapies to inhibit the development of glomerulosclerosis.

AB - Background/Aims: The role of matrix metalloproteinases (MMPs) in the pathogenesis of glomerular injury appears to be complex. To investigate the role of individual MMPs, we examined the course of Adriamycin-induced albuminuria and glomerulosclerosis in mice lacking either a gelatinase (MMP-9) or a collagenase (MMP-13). Methods: Adriamycin was administered to MMP-9 or MMP-13 knockout (KO) mice. Glomerular injury was assessed by the quantification of albuminuria, the glomerular injury score and type IV collagen immunostaining. Results: Treatment of mice with Adriamycin (18 mg/kg i.v.) resulted in marked albuminuria and glomerulosclerosis reaching a peak at 4-8 weeks. The albuminuria and glomerulosclerosis were significantly (p < 0.05) attenuated in both the MMP-9 KO and MMP-13 KO mice compared to controls. In contrast, treatment of wild-type mice with the broad-spectrum MMP inhibitor doxycycline did not have a beneficial effect on the albuminuria and glomerulosclerosis. Conclusion: These results support a role for both gelatinase (MMP-9) and collagenase (MMP-13) in the pathogenesis of glomerular injury in the Adriamycin-induced glomerulosclerosis model. MMP inhibitors with high specificity towards MMP-9 and/or MMP-13 may be potential future candidates to provide more effective therapies to inhibit the development of glomerulosclerosis.

KW - Adriamycin

KW - Glomerulosclerosis

KW - Matrix metalloproteinase

UR - http://www.scopus.com/inward/record.url?scp=77950941022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950941022&partnerID=8YFLogxK

U2 - 10.1159/000312883

DO - 10.1159/000312883

M3 - Article

C2 - 20407279

AN - SCOPUS:77950941022

VL - 115

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 1660-8151

IS - 2

ER -